Teleflex (NYSE:TFX) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen downgraded shares of Teleflex (NYSE:TFX) from a hold rating to a sell rating in a report published on Saturday.

Several other analysts have also weighed in on TFX. Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a report on Wednesday, June 24th. Truist Financial reaffirmed a “hold” rating and set a $143.00 target price (up from $135.00) on shares of Teleflex in a report on Monday, May 11th. UBS Group started coverage on shares of Teleflex in a research report on Tuesday. They issued a “neutral” rating and a $145.00 price target on the stock. Royal Bank Of Canada raised shares of Teleflex from a “sector perform” rating to an “outperform” rating and upped their price target for the company from $135.00 to $155.00 in a report on Friday, May 8th. Finally, Piper Sandler upgraded shares of Teleflex from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $140.00 to $160.00 in a research report on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $148.90.

Teleflex Price Performance

NYSE TFX opened at $136.72 on Friday. Teleflex has a 12 month low of $100.18 and a 12 month high of $139.67. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.55 and a quick ratio of 2.03. The firm has a market capitalization of $6.05 billion, a PE ratio of -6.00, a P/E/G ratio of 1.02 and a beta of 0.82. The company’s 50 day simple moving average is $130.96 and its 200 day simple moving average is $121.37.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, May 7th. The medical technology company reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $1.21 by $0.18. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.The firm had revenue of $548.30 million during the quarter, compared to the consensus estimate of $536.91 million. During the same period in the prior year, the firm posted $1.44 earnings per share. The firm’s revenue for the quarter was up 32.3% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. As a group, equities research analysts forecast that Teleflex will post 6.7 EPS for the current fiscal year.

Teleflex Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Monday, May 25th were paid a dividend of $0.34 per share. The ex-dividend date of this dividend was Friday, May 22nd. This represents a $1.36 annualized dividend and a dividend yield of 1.0%. Teleflex’s dividend payout ratio (DPR) is currently -5.96%.

Hedge Funds Weigh In On Teleflex

A number of hedge funds have recently modified their holdings of TFX. Ruffer LLP purchased a new position in Teleflex in the 4th quarter worth about $5,154,000. Waterfront Wealth Inc. purchased a new stake in Teleflex during the fourth quarter valued at about $2,050,000. Eos Management L.P. acquired a new position in shares of Teleflex in the fourth quarter worth about $3,763,000. Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in shares of Teleflex by 227.5% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 27,822 shares of the medical technology company’s stock worth $3,395,000 after buying an additional 19,327 shares during the period. Finally, First Eagle Investment Management LLC increased its position in shares of Teleflex by 163.4% in the fourth quarter. First Eagle Investment Management LLC now owns 84,300 shares of the medical technology company’s stock worth $10,288,000 after acquiring an additional 52,300 shares in the last quarter. 95.62% of the stock is currently owned by institutional investors and hedge funds.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.